Table 2. MiRNAs involved in CDDP-resistance of NSCLC cells mainly assigned to apoptosis pathway.
| miRNA | Targets | Cells / Tissue | Expression | Function | Reference |
|---|---|---|---|---|---|
| miR-10a | RhoE, MDR1, MRP1 | A549/CDDP | up | Inhibits apoptosis, enhances drug efflux | [62] |
| miR-21 | E2F-1, TWIST, PTEN | NSCLC tissue, NSCLC cells, A549/CDDP | up | Inhibits apoptosis, blocks the cell cycle, increases CDDP-resistance | [54, 119, 120] |
| miR-26a | HMGA2 | A549/CDDP | down | Regulates E2F1-Akt pathway | [121] |
| miR-31 | ABCB9 | CDDP-resistant NSCLC cells | up | Anti-apoptotic effects via ABCB9 inhibition | [67] |
| miR-96 | SAMD9 | NSCLC tissue, NSCLC cells | up | Down-regulates SAMD9 expression, decreases apoptosis | [64] |
| miR-98 | HMGA2, PAK1 | A549/CDDP, NSCLC tissue, A549/PAR | down | Modulates apoptosis via HMGA2, inversely regulates PAK1, inhibits apoptosis | [50, 51] |
| miR-106a | ABCA1 | A549/CDDP | up | Represses apoptosis, decreases CDDP-uptake | [68] |
| miR-128-2 | E2F5 | NSCLC cells | up | Inhibits apoptosis, increases resistance to CDDP | [61] |
| miR-135a/b | MCL1 | A549/CDDP | down | Modulates apoptosis via MCL1, overexpression sensitizes A549/CDDP | [49] |
| miR-137 | CASP3 | NSCLC cells overexpressing miR-137 | up | Decreases CASP3 expression and cell death | [122] |
| miR-138 | ERCC1, EZH2, CCND3 | A549/CDDP | up | Increases sensitivity to CDDP and apoptosis | [38–40] |
| miR-141 | PDCD4 | A549/CDDP vs. A549/PAR | up | Contributes to CDDP-resistance by suppressing PDCD4 | [65] |
| miR-148b | DNMT1 | A549/CDDP, SPC-A1/CDDP | down | Influence CDDP-sensitivity, cell viability and apoptosis | [57] |
| miR-155 | APAF-1 | NSCLC tissue, A549/PAR | up | Inhibits sensitivity to CDDP via negative regulation of Apaf-1 | [37] |
| miR-181a | n. d. | CDDP- treated A549/PAR | up | Enhances CDDP-triggered mitochondrial apoptosis | [13] |
| miR-181b | BCL2 | A549/CDDP | down | Modulation of CDDP-induced apoptosis via targeting BCL2 | [123] |
| miR-184 | BCL2 | NSCLC tissue | down | Decrease of miR-184 by E6 predicts unfavorable response to CDDP | [30] |
| miR-192 | BIM, BCL2 | A549/PAR, A549/CDDP | up | Inhibits apoptosis via Bcl2, induces CDDP-resistance | [28, 29] |
| miR-196a | n. d. | NSCLC tissue, NSCLC cells | up | Increases CDDP-resistance by inhibiting apoptosis | [124] |
| miR-200bc/429 cl. | BCL2, XIAP | A549/CDDP | down | Inversely regulates BCL2/XIAP expression and apoptosis | [125] |
| miR-212 | AChE | CDDP-treated A549/PAR | down | Anti-apoptotic effects through AChE repression | [60] |
| miR-216a | eIF4B, ZEB1 | NSCLC tissue | down | Suppresses NSCLC growth and metastasis, enhances apoptosis | [12] |
| miR-218 | RUNX2 | NSCLC tissue, NSCLC cells | down | Increases resistance to CDDP via targeting RUNX2 | [63] |
| miR-379 | EIF4G | NSCLC tissue, NSCLC cells | down | Tumor suppressor, influences CDDP-induced apoptosis by targeting EIF4G | [66] |
| miR-451 | MCL-1 | NSCLC tissue, A549/PAR, A549/CDDP | up / down | Tumor suppressor, inhibits growth and apoptosis by inactivating Akt pathway | [47, 48] |
| miR-497 | BCL2 | A549/CDDP | down | Modulation of CDDP-induced apoptosis via targeting BCL2 | [35] |
| miR-503 | BCL2 | A549/CDDP | down | Increases resistance to CDDP via targeting BCL2 | [55] |
| miR-513-3p | GSTP1 | A549/CDDP | down | Enhances CDDP-induced apoptosis | [126] |
| miR-630 | n. d. | CDDP- treated A549/PAR | up | Reduces CDDP-triggered mitochondrial apoptosis | [13] |
| miR-1244 | TP53 | A549/CDDP, A549/PAR | down | Reduces cell proliferation, survival and invasion | [83] |
| Let-7c | ABCC2, BCL-XL | A549/CDDP | down | Modulates CDDP-response by targeting ABCC2 and BCL-XL | [36] |
cl., cluster; n. d., not defined; Expression = expression in CDDP-resistant cells or NSCLC tissue in comparison to sensitive cells or non-malignant lung tissue.